This application generally relates to medical devices. More particularly, this application relates to esophageal stents and related methods.
The embodiments disclosed herein will become more fully apparent from the following description and appended claims, taken in conjunction with the accompanying drawings. These drawings depict only typical embodiments, which will be described with additional specificity and detail through use of the accompanying drawings in which:
Stents are disclosed herein. In some embodiments, the stents described herein comprise a hollow cylindrical body having an interior dimension and comprising a middle region that extends to a first end and also extends to an opposing second end. The interior dimension refers to the three-dimensional space within the stent. As used herein, the hollow cylindrical body may refer to generally cylindrical shapes and forms, including stents with flared ends, for example. The first end and the second end can each comprise a plurality of flanges, within which the flanges can have either similar or different characteristics, particularly physical profiles.
Embodiments may be understood by reference to the drawings, wherein like parts are designated by like numerals throughout. It will be readily understood by one of ordinary skill in the art having the benefit of this disclosure that the components of the embodiments, as generally described and illustrated in the figures herein, could be arranged and designed in a wide variety of different configurations. Thus, the following more detailed description of various embodiments, as represented in the figures, is not intended to limit the scope of the disclosure, but is merely representative of various embodiments. While the various aspects of the embodiments are presented in drawings, the drawings are not necessarily drawn to scale unless specifically indicated.
It will be appreciated that various features are sometimes grouped together in a single embodiment, figure, or description thereof for the purpose of streamlining the disclosure. Many of these features may be used alone and/or in combination with one another.
The phrases “coupled to” and “in communication with” refer to any form of interaction between two or more entities, including mechanical, electrical, magnetic, electromagnetic, fluid, and thermal interaction. Two components may be coupled to or in communication with each other even though they are not in direct contact with each other. For example, two components may be coupled to or in communication with each other through an intermediate component.
The directional terms “distal” and “proximal” are given their ordinary meaning in the art. That is, the distal end of a medical device means the end of the device furthest from the practitioner during use. The proximal end refers to the opposite end, or the end nearest the practitioner during use. As applied a stent deployed within an esophagus, the proximal end of the stent refers to the end closest to the patient's head, and the distal end of the stent refers to the opposite end, the end closer to the patient's stomach.
In an aspect, one end of the stent body will be the proximal end and the other will be the distal end as defined herein. In some embodiments, the stent is configured so that either the first end or the second end can be proximal with the remaining end being distal based on the practitioner's choice. In other embodiments, use of the stent indicates that a specific end is consistently designated as the proximal end. In such embodiments described herein, the first end is intended for designation as the proximal end and the second end is intended for designation as the distal end unless expressly indicated otherwise.
In the illustrated embodiments, each of the ends comprises a plurality of flanges, flares, or flared regions that extend radially from the circumference 114 of the middle region 104. However, it should be noted that embodiments in which only one end includes these and other features described herein are also encompassed by the present disclosure. These flanges are configured to interact with the surfaces of a lumen in the body of a subject into which the stent 100 is deployed (e.g., such as the esophagus). More specifically, the first end 106 comprises a first plurality of flanges 116 and the second end 108 comprises a second plurality of flanges 118. As shown, each of the first plurality and the second plurality include at least two flanges. More specifically, the first plurality of flanges 116 includes an inner flange 120a adjacent to the middle region 104 and an outer flange 122a adjacent to the first opening 110, and the second plurality of flanges 118 similarly includes an inner flange 120b adjacent to the opposing end of the middle region 104 and an outer flange 122b adjacent to the second opening 112. As used herein in discussing the shapes and arrangement of flanges, “inner” refers to the side facing or in the direction of the middle region, while “outer” refers to the side facing or in the direction of the nearest opening. Additionally, while the embodiments shown herein depict a plurality of flanges on each end, it will also be appreciated that in some embodiments only one end of the stent includes a plurality of flanges, while the opposing end includes a singular flange.
As shown in
As noted above, the outer flange 122 defines the adjacent opening into the interior of the stent. The profile of the outer flange 122 comprises an inner shoulder 134 extending from the circumference 114 or valley 130 to a peak 136. In some embodiments, the peak 136 of the outer flange 122 is the same height relative to the circumference 114 as the peak 126 of the inner flange 120. In certain embodiments, as exemplified by
In some embodiments, the overall length of the stent may range from about 30 mm to about 250 mm, including ranging from about 30 mm to about 70 mm or from about 160 mm to about 250 mm. In some embodiments, the length of the first end and/or the second end (which can include the plurality of flanges) in the unelongated and unstretched state may each range from about 10 mm to about 30 mm, including ranging from about 14 mm to about 22 mm. In some embodiments, the length of the middle region may range from about 5 mm to about 210 mm, including ranging from about 10 mm to about 30 mm and from about 30 mm to about 120 mm and from about 120 mm to about 210 mm. Smaller and/or larger stents are also contemplated depending on the desired use. For example, in some embodiments, the stents are configured for deployment within the esophagus. However, the disclosure is not so limited and other types of stents are also contemplated, including, but not limited to, gastrointestinal stents (including colonic stents), biliary stents, lung stents, vascular stents, transluminal stents, pancreatic stents, etc.
As shown in
In some embodiments, the braid pattern may lead to differing cell requirements over the length of the stent 100, where a cell refers to the design created by the braid pattern. Thus, depending on stent length and braid pattern, the braid designs may result in fractional and non-fractional cell counts. For example, a stent may be designed with a non-fractional cell count, in which a full braid pattern is completed on each end of the stent and/or the stent comprises only full braid patterns along the length of the stent. Non-fractional cell counts refer to a whole cell count. For example, a stent with a non-fractional cell count may have, 20, 30, 40, 50, or more full cell counts, or full braid patterns along its length. Fractional cell counts refer to fractional cell count numbers, 20.5, 30.5, 40.5, 50.5 or more, meaning the stent has a whole number of full cell counts in addition to a partial cell (or braid pattern) along the length of the stent. In some embodiments, the braid pattern may be one over one and may have a fractional or non-fractional cell count. In some embodiments, the braid pattern may be one over two and may have a fractional or non-fractional cell count.
As shown in
The pitch (i.e., axial distance between crossing strands) also impacts the compressibility and stiffness of the braided or woven wires. In an aspect, a sufficiently tight pitch can impart better migration resistance to the stent. The pitch is related to the number of strands interwoven (or interbraided) with each other and the braid angle α, and therefore can vary over different geometries. In some embodiments, the pitch is substantially constant over the middle region. In some embodiments, the pitch is substantially uniform at a peak of a flange while varying uniformly over the inner shoulder and the outer taper.
The braided or woven wires may be braided or woven in a given pattern in accordance with an appropriate braid design, such as a closed-loop braid design, a single wire woven design, an endless braid design, or the like. In some embodiments, the wire is braided in a closed-loop braid design in which multiple strands are interlaced in a first direction (e.g., a distal direction) and then turn and are interlaced back in an opposite second direction (e.g., back in the proximal direction). In still other embodiments, the stent may have an endless braid design in which multiple strands are interlaced. In some embodiments, the braid pattern can comprise hook stitches. In other embodiments, a “hook and cross” braid pattern is used in which the pattern includes both hook stitches and cross stitches. In some embodiments, the braid pattern is created using an axial braiding approach. In some embodiments, the braid pattern is created using a radial braiding approach. Radial braiding involves creating a fractional cell count along the length of the stent, either a non-fractional or a fractional cell count can be selected with axial braiding.
In various embodiments, the braided or woven wires are braided or woven so as to create a series of loops at one or both ends of the stent. The arrangement of these loops can be selected to provide desired functionality, such as for threading through of a suture line (discussed further below). In some embodiments the end loops are substantially aligned in one plane at the stent opening (see e.g.,
The braided or woven wires may include varying numbers of strands, where the number used can depend in part upon the size of the stent and the braid or weave pattern. In some embodiments, the stent includes a wire count of from 32 to 64 wires, or more particularly from 45 to 50 wires, or more particularly from 48-56 wires.
When braided or woven in a closed-loop braid design, the braided or woven wires may start and stop at various locations on the stent 100. In an aspect, it can be advantageous to design the braid so that such termination points occur on surfaces that include a substantially flat dimension. In some embodiments, at least one wire termination point is on the middle region of the stent. In certain embodiments, such as the embodiment illustrated in
In various embodiments, the braided or woven wires forming the stent may comprise any suitable material known in the art, including plastics and memory alloys. In some embodiments, the wires may be Nitinol, including ASTM F2063. In certain embodiments, the thickness of a memory alloy strand of the braided or woven wires may be about 140 μm to about 191 μm. In other embodiments, the thickness may be about 165 μm to about 178 μm. Generally speaking, smaller wires may be used with smaller diameter stents and larger diameter wires may be used with larger diameter stents. Also, while smaller diameter wires can be used for stents designed for “through-the-scope” placement, stents designed for “over the wire” placement can include wires having significantly larger diameters. Radiopaque markers and/or coils can also be incorporated into the stent as desired.
Additional aspects of the flanges in the embodiments described above are illustrated in
The perpendicularly oriented region (or more perpendicularly oriented region having a steeper or more inclined angle, slope, or arc) of the inner shoulder 124 results in the peak 126 and, more generally the inner flange 120, exerting a hoop force against the tissue walls of a lumen in a subject so as to facilitate greater retention of the stent 100 in the body lumen. In another sense, the shape of the inner flange 120 functions as a shoulder region that resists longitudinal migration of the stent 100 due to peristalsis or other forces, in a manner that is independent of the magnitude of the hoop force. The shallower incline, angle, slope, or arc of the outer taper 128 increases stiffness of the inner flange 120 as compared to a flange that includes a perpendicular region on both inner and outer faces. For example, a flange having a symmetrical profile can tend to deflect more outwardly when in use, as compared to embodiments where the inner shoulders include more perpendicular regions, but the outer tapers do not include corresponding perpendicular regions.
The same aspects apply to each outer flange in embodiments in which said outer flange has a similar profile to that of the inner flange, such as with the outer flange 122a having a tapered outer section 138a′ in the embodiment illustrated in
In an aspect, the magnitude and nature of these effects can vary based on physical dimensions of the outer section, such as its length and diameter. For example, attaining such performance from a stent of a particular size may involve said stent including an outer section having a minimum length. On the other hand, increasing the length of the outer section means a concomitant increase in the overall length of the stent, which in turn can be limited by the particular clinical use. In various embodiments, the length of the outer segment can be selected so as to provide sufficient retention and sealing performance while keeping the overall stent length within applicable parameters for the intended use. Another consideration is provided where the cylindrical outer section is used as a termination surface for the woven or braided wire from which the stent body is made. Accordingly, in some embodiments, the outer segment has a length equal to at least one cell of the braid pattern.
The benefits of increased stiffness and strength provided by the flange shapes described above can be enhanced by combining two or more flanges in a “stacked” configuration in accordance with the various embodiments described herein. Without being bound or limited by a particular theory, the retention forces generated by the individual flanges can increase as a function of the number of flanges arranged together. Stated another way, in a plurality of flanges, one flange can increase the resistance of an adjacent flange to deformation and vice versa, thereby increasing the capacity of both flanges to resist migration of the stent.
The cover may be elastomeric, polymeric, or comprised of any other material known in the art. In some embodiments, the cover may include silicone, while in certain embodiments the cover may be comprised only of silicone. In some embodiments, the cover may be applied such that it tends to ebb and flow into spaces between portions of the braided or woven wires, resulting in a “tire tread” like outer surface, rather than a smooth outer cover. This can allow tissue to lock into the uneven spaces and treads, thus adding anti-migration properties in some embodiments. In some embodiments, the cover is shaped such that the braided or woven wires are uncovered in some regions of the stent, which can allow tissue to grow into these spaces to help secure the stent in place. For instance, the peaks of the flanges can be at least partially uncovered, which can allow tissue ingrowth. In some embodiments, the cover can comprise two or more layers of material.
The stent 200 in
As discussed above, certain benefits can be realized in stents having two or more flanges in a stacked arrangement at each end, including an increased capacity to retain the stent's position in a lumen. Accordingly, in some embodiments a plurality of flanges can include one or more additional flanges situated between the inner flange and outer flange. For instance, one, two, three, four or more additional flanges may be disposed between the inner and outer flanges, resulting in a total of three, four, five, six, or more total flanges on an end of the stent. Further, in some embodiments, a proximal end of the stent can be configured with additional flanges (or more flanges) than the distal end to aid in preventing migration of the stent. Such an arrangement can be advantageous, although not required, when employing the stent in an esophagus.
Stents as described above, may include additional features, including but not limited to anti-migration features, adhesives, and the like. For instance, a strip of a specialized material can be disposed on an external surface of the stent. In some embodiments, the specialized material provides a textured surface. In certain embodiments, the textured surface provides increased and/or decreased friction with surfaces into which the stent comes into contact, e.g., a tissue surface, as compared to the other regions of the outer surface of the stent body. In a particular example, the textured surface includes a multilayered/micropatterned surface in which friction is dependent on conditions in its environment, for example the wetness of the material. Examples of such materials are described in U.S. Patent Application Publication Nos. 2011/0311764 and 2017/0014111. In an aspect, such material can provide the stent with enhanced grip on surrounding tissues with less injury to said tissues. In some embodiments, a specialized material can be disposed on the external surface of the entirety of the stent, or of a designated portion thereof. For instance, as shown in the stent 600 in
Any methods disclosed herein comprise one or more steps or actions for performing the described method. The method steps and/or actions may be interchanged with one another. In other words, unless a specific order of steps or actions is required for proper operation of the embodiment, the order and/or use of specific steps and/or actions may be modified.
References to approximations are made throughout this specification, such as by use of the terms “substantially” and “about.” For each such reference, it is to be understood that, in some embodiments, the value, feature, or characteristic may be specified without approximation. For example, where qualifiers such as “about” and “substantially” are used, these terms include within their scope the qualified words in the absence of their qualifiers. For example, where the term “substantially perpendicular” is recited with respect to a feature, it is understood that in further embodiments, the feature can have a precisely perpendicular configuration. All ranges also include both endpoints.
Similarly, in the above description of embodiments, various features are sometimes grouped together in a single embodiment, figure, or description thereof for the purpose of streamlining the disclosure. This method of disclosure, however, is not to be interpreted as reflecting an intention that any claim require more features than those expressly recited in that claim. Rather, as the following claims reflect, inventive aspects lie in a combination of fewer than all features of any single foregoing disclosed embodiment.
The claims following this written disclosure are hereby expressly incorporated into the present written disclosure, with each claim standing on its own as a separate embodiment. This disclosure includes all permutations of the independent claims with their dependent claims. Moreover, additional embodiments capable of derivation from the independent and dependent claims that follow are also expressly incorporated into the present written description.
Without further elaboration, it is believed that one skilled in the art can use the preceding description to utilize the invention to its fullest extent. The claims and embodiments disclosed herein are to be construed as merely illustrative and exemplary, and not a limitation of the scope of the present disclosure in any way. It will be apparent to those having ordinary skill in the art, with the aid of the present disclosure, that changes may be made to the details of the above-described embodiments without departing from the underlying principles of the disclosure herein. In other words, various modifications and improvements of the embodiments specifically disclosed in the description above are within the scope of the appended claims. Moreover, the order of the steps or actions of the methods disclosed herein may be changed by those skilled in the art without departing from the scope of the present disclosure. In other words, unless a specific order of steps or actions is required for proper operation of the embodiment, the order or use of specific steps or actions may be modified. The scope of the invention is therefore defined by the following claims and their equivalents.
This application claims priority to U.S. Provisional Application No. 63/056,471, filed Jul. 24, 2020, and titled ESOPHAGEAL STENTS AND RELATED METHODS, which is incorporated herein by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
4913141 | Hillstead | Apr 1990 | A |
5201757 | Heyn et al. | Apr 1993 | A |
5413575 | Haenggi | May 1995 | A |
5534007 | Germain et al. | Jul 1996 | A |
5591172 | Bachmann et al. | Jan 1997 | A |
5591196 | Marin et al. | Jan 1997 | A |
5603698 | Roberts et al. | Feb 1997 | A |
5645559 | Hachtman et al. | Jul 1997 | A |
5733325 | Robinson et al. | Mar 1998 | A |
5755769 | Richard et al. | May 1998 | A |
5759186 | Bachmann et al. | Jun 1998 | A |
5824041 | Lenker et al. | Oct 1998 | A |
5868755 | Kanner et al. | Feb 1999 | A |
5876448 | Thompson et al. | Mar 1999 | A |
5916147 | Boury | Jun 1999 | A |
5944727 | Ahari et al. | Aug 1999 | A |
5968052 | Sullivan, III et al. | Oct 1999 | A |
6015429 | Lau et al. | Jan 2000 | A |
6093194 | Mikus et al. | Jul 2000 | A |
6123715 | Amplatz | Sep 2000 | A |
6143021 | Staehle | Nov 2000 | A |
6146415 | Fitz | Nov 2000 | A |
6162231 | Mikus et al. | Dec 2000 | A |
6241757 | An et al. | Jun 2001 | B1 |
6270524 | Kim | Aug 2001 | B1 |
6283992 | Hankh et al. | Sep 2001 | B1 |
6368339 | Amplatz | Apr 2002 | B1 |
6383211 | Staehle | May 2002 | B1 |
6391051 | Sullivan, III et al. | May 2002 | B2 |
6413269 | Bui et al. | Jul 2002 | B1 |
6416545 | Mikus et al. | Jul 2002 | B1 |
6428566 | Holt | Aug 2002 | B1 |
6443980 | Wang et al. | Sep 2002 | B1 |
6447531 | Amplatz | Sep 2002 | B1 |
6514261 | Randall et al. | Feb 2003 | B1 |
6520983 | Colgan et al. | Feb 2003 | B1 |
6530933 | Yeung et al. | Mar 2003 | B1 |
6599296 | Gillick et al. | Jul 2003 | B1 |
6599308 | Amplatz | Jul 2003 | B2 |
6613079 | Wolinsky et al. | Sep 2003 | B1 |
6616675 | Evard et al. | Sep 2003 | B1 |
6629981 | Dennis et al. | Oct 2003 | B2 |
6645143 | VanTassel et al. | Nov 2003 | B2 |
6669719 | Wallace et al. | Dec 2003 | B2 |
6726712 | Raeder-Devens et al. | Apr 2004 | B1 |
6746480 | Scholz et al. | Jun 2004 | B2 |
6770101 | Desmond, III et al. | Aug 2004 | B2 |
6776791 | Jody et al. | Aug 2004 | B1 |
6821295 | Farrar | Nov 2004 | B1 |
6866669 | Buzzard et al. | Mar 2005 | B2 |
6893413 | Martin | May 2005 | B2 |
6926732 | Derus et al. | Aug 2005 | B2 |
6955685 | Escamilla et al. | Oct 2005 | B2 |
7004966 | Edwin et al. | Feb 2006 | B2 |
7083640 | Lombardi et al. | Aug 2006 | B2 |
7309350 | Landreville et al. | Dec 2007 | B2 |
7309351 | Escamilla et al. | Dec 2007 | B2 |
7335224 | Ohlenschaeger | Feb 2008 | B2 |
7393357 | Stelter et al. | Jul 2008 | B2 |
7473271 | Gunderson | Jan 2009 | B2 |
7591848 | Allen | Sep 2009 | B2 |
7637942 | Mangiardi et al. | Dec 2009 | B2 |
7731654 | Mangiardi et al. | Jun 2010 | B2 |
7959671 | Mangiardi et al. | Jun 2011 | B2 |
8012194 | Edwin et al. | Sep 2011 | B2 |
8206436 | Mangiardi et al. | Jun 2012 | B2 |
8262719 | Erickson et al. | Sep 2012 | B2 |
8357193 | Phan et al. | Jan 2013 | B2 |
8414635 | Hyodoh et al. | Apr 2013 | B2 |
8425539 | Binmoeller et al. | Apr 2013 | B2 |
8439934 | Satasiya et al. | May 2013 | B2 |
8454632 | Binmoeller et al. | Jun 2013 | B2 |
8518099 | Chanduszko et al. | Aug 2013 | B2 |
8524132 | Von Oepen et al. | Sep 2013 | B2 |
8535366 | Mangiardi et al. | Sep 2013 | B2 |
8652099 | Fierens et al. | Feb 2014 | B2 |
8677874 | Lilburn et al. | Mar 2014 | B2 |
8696611 | Yaacov et al. | Apr 2014 | B2 |
8715334 | Clerc et al. | May 2014 | B2 |
8834558 | Nissl | Sep 2014 | B2 |
8906081 | Cully et al. | Dec 2014 | B2 |
8926683 | Darla et al. | Jan 2015 | B2 |
9107741 | Bui et al. | Aug 2015 | B2 |
9155643 | Clerc et al. | Oct 2015 | B2 |
9192496 | Robinson | Nov 2015 | B2 |
9259336 | Schaeffer et al. | Feb 2016 | B2 |
9284637 | Boyle et al. | Mar 2016 | B2 |
9381041 | Brown et al. | Jul 2016 | B2 |
10285834 | Cindrich et al. | May 2019 | B2 |
20010037141 | Yee et al. | Nov 2001 | A1 |
20020138095 | Mazzocchi et al. | Sep 2002 | A1 |
20020151967 | Mikus et al. | Oct 2002 | A1 |
20020183827 | Derus et al. | Dec 2002 | A1 |
20020193749 | Olovson | Dec 2002 | A1 |
20030023268 | Lizardi | Jan 2003 | A1 |
20030028236 | Gillick | Feb 2003 | A1 |
20030050686 | Raeder-Devens et al. | Mar 2003 | A1 |
20030135265 | Stinson | Jul 2003 | A1 |
20030135268 | Desai | Jul 2003 | A1 |
20030144671 | Brooks et al. | Jul 2003 | A1 |
20030167060 | Buzzard et al. | Sep 2003 | A1 |
20040030381 | Shu | Feb 2004 | A1 |
20040098077 | Gianotti | May 2004 | A1 |
20040127973 | Mangiardi et al. | Jul 2004 | A1 |
20040181239 | Dorn et al. | Sep 2004 | A1 |
20040193243 | Mangiardi et al. | Sep 2004 | A1 |
20040267281 | Harari et al. | Dec 2004 | A1 |
20050027345 | Horan et al. | Feb 2005 | A1 |
20050038495 | Greenan | Feb 2005 | A1 |
20050090887 | Pryor | Apr 2005 | A1 |
20050125050 | Carter et al. | Jun 2005 | A1 |
20050149160 | McFerran | Jul 2005 | A1 |
20050182475 | Jen et al. | Aug 2005 | A1 |
20050182481 | Schlick et al. | Aug 2005 | A1 |
20050278010 | Richardson | Dec 2005 | A1 |
20050283179 | Lentz | Dec 2005 | A1 |
20060020321 | Parker | Jan 2006 | A1 |
20060155368 | Shin | Jul 2006 | A1 |
20060184224 | Angel | Aug 2006 | A1 |
20060258972 | Mangiardi et al. | Nov 2006 | A1 |
20060259113 | Nissl | Nov 2006 | A1 |
20070005122 | Inoue | Jan 2007 | A1 |
20070043421 | Mangiardi et al. | Feb 2007 | A1 |
20070100421 | Griffin | May 2007 | A1 |
20070135904 | Eidenschink et al. | Jun 2007 | A1 |
20070156225 | George et al. | Jul 2007 | A1 |
20070179590 | Lu et al. | Aug 2007 | A1 |
20070208350 | Gunderson | Sep 2007 | A1 |
20070250150 | Pal et al. | Oct 2007 | A1 |
20070270932 | Headley et al. | Nov 2007 | A1 |
20080114443 | Mitchell et al. | May 2008 | A1 |
20080140178 | Rasmussen et al. | Jun 2008 | A1 |
20080228256 | Erickson et al. | Sep 2008 | A1 |
20080288042 | Purdy et al. | Nov 2008 | A1 |
20090099636 | Chanduszko et al. | Apr 2009 | A1 |
20090099647 | Glimsdale et al. | Apr 2009 | A1 |
20090118740 | Mangiardi et al. | May 2009 | A1 |
20090157158 | Ondracek | Jun 2009 | A1 |
20090171427 | Melsheimer et al. | Jul 2009 | A1 |
20090171433 | Melsheimer | Jul 2009 | A1 |
20090187240 | Clerc | Jul 2009 | A1 |
20090192518 | Golden et al. | Jul 2009 | A1 |
20090292262 | Adams et al. | Nov 2009 | A1 |
20100023032 | Granja et al. | Jan 2010 | A1 |
20100023132 | Imran | Jan 2010 | A1 |
20100030256 | Dubrul et al. | Feb 2010 | A1 |
20100030321 | Mach | Feb 2010 | A1 |
20100049295 | Satasiya et al. | Feb 2010 | A1 |
20100057145 | Bhatnagar et al. | Mar 2010 | A1 |
20100057185 | Melsheimer et al. | Mar 2010 | A1 |
20100070016 | Dorn | Mar 2010 | A1 |
20100145431 | Wu et al. | Jun 2010 | A1 |
20100252470 | Ryan et al. | Oct 2010 | A1 |
20110004290 | Bales, Jr. et al. | Jan 2011 | A1 |
20110015616 | Straubinger et al. | Jan 2011 | A1 |
20110082464 | Douk et al. | Apr 2011 | A1 |
20110137396 | Dorn et al. | Jun 2011 | A1 |
20110137400 | Dorn et al. | Jun 2011 | A1 |
20110190862 | Bashiri et al. | Aug 2011 | A1 |
20110208296 | Duffy et al. | Aug 2011 | A1 |
20110264191 | Rothstein | Oct 2011 | A1 |
20110288482 | Farrell et al. | Nov 2011 | A1 |
20110307070 | Clerc et al. | Dec 2011 | A1 |
20110319980 | Ryan | Dec 2011 | A1 |
20120046729 | Von Oepen et al. | Feb 2012 | A1 |
20120095567 | Weisman et al. | Apr 2012 | A1 |
20120136426 | Phan et al. | May 2012 | A1 |
20120290066 | Nabulsi et al. | Nov 2012 | A1 |
20120296257 | Van et al. | Nov 2012 | A1 |
20120303109 | Okuma | Nov 2012 | A1 |
20120303112 | Armstrong et al. | Nov 2012 | A1 |
20120310320 | Gill et al. | Dec 2012 | A1 |
20130018215 | Snider et al. | Jan 2013 | A1 |
20130103163 | Krimsky et al. | Apr 2013 | A1 |
20130110221 | Campbell et al. | May 2013 | A1 |
20130116770 | Robinson | May 2013 | A1 |
20130116771 | Robinson | May 2013 | A1 |
20130116772 | Robinson et al. | May 2013 | A1 |
20130158673 | Toomey | Jun 2013 | A1 |
20130184833 | Ryan et al. | Jul 2013 | A1 |
20130197623 | McHugo | Aug 2013 | A1 |
20130231689 | Binmoeller et al. | Sep 2013 | A1 |
20130253546 | Sander et al. | Sep 2013 | A1 |
20130274870 | Lombardi et al. | Oct 2013 | A1 |
20130310833 | Brown et al. | Nov 2013 | A1 |
20140074065 | Muni et al. | Mar 2014 | A1 |
20140074219 | Hingston et al. | Mar 2014 | A1 |
20140171863 | Blacker | Jun 2014 | A1 |
20140236064 | Binmoeller et al. | Aug 2014 | A1 |
20140243992 | Walsh et al. | Aug 2014 | A1 |
20140277573 | Gill et al. | Sep 2014 | A1 |
20140288636 | Headley, Jr. et al. | Sep 2014 | A1 |
20140303709 | Dwork | Oct 2014 | A1 |
20140330305 | Rood et al. | Nov 2014 | A1 |
20140350694 | Behan | Nov 2014 | A1 |
20140364959 | Attar et al. | Dec 2014 | A1 |
20150066128 | Losordo et al. | Mar 2015 | A1 |
20150100133 | Xie et al. | Apr 2015 | A1 |
20150112377 | Arnone et al. | Apr 2015 | A1 |
20150173919 | Baldwin | Jun 2015 | A1 |
20150230955 | Farag Eells et al. | Aug 2015 | A1 |
20150313595 | Houshton et al. | Nov 2015 | A1 |
20150313599 | Johnson et al. | Nov 2015 | A1 |
20160081823 | Majercak | Mar 2016 | A1 |
20160081832 | Hingston et al. | Mar 2016 | A1 |
20160242846 | Brown et al. | Aug 2016 | A1 |
20160256306 | Cindrich et al. | Sep 2016 | A1 |
20170014133 | Han et al. | Jan 2017 | A1 |
20170035424 | Binmoeller et al. | Feb 2017 | A1 |
20170035426 | Phan et al. | Feb 2017 | A1 |
20170035427 | Sander et al. | Feb 2017 | A1 |
20170035428 | Binmoeller et al. | Feb 2017 | A1 |
20170354404 | Chu | Dec 2017 | A1 |
20180185183 | Christakis et al. | Jul 2018 | A1 |
20180193175 | Bluecher et al. | Jul 2018 | A1 |
20180263797 | Eller et al. | Sep 2018 | A1 |
20180280166 | Walsh et al. | Oct 2018 | A1 |
20180303594 | Eller et al. | Oct 2018 | A1 |
20180338846 | Folan et al. | Nov 2018 | A1 |
20190099589 | Walsh et al. | Apr 2019 | A1 |
20190254804 | Folan | Aug 2019 | A1 |
20200375768 | Eller et al. | Dec 2020 | A1 |
20210121306 | Henchie | Apr 2021 | A1 |
20210145563 | Folan | May 2021 | A1 |
20210161692 | Mower et al. | Jun 2021 | A1 |
20220125608 | Ethridge et al. | Apr 2022 | A1 |
20230381000 | Eller et al. | Nov 2023 | A1 |
Number | Date | Country |
---|---|---|
210185778 | Mar 2020 | CN |
4323866 | Jan 1994 | DE |
102005051469 | Apr 2007 | DE |
0364420 | Apr 1990 | EP |
0408245 | Jan 1991 | EP |
0872220 | Oct 1998 | EP |
1637092 | Mar 2006 | EP |
2522316 | Nov 2012 | EP |
199631174 | Oct 1996 | WO |
200018330 | Apr 2000 | WO |
2000078246 | Dec 2000 | WO |
2002056798 | Jul 2002 | WO |
2002087470 | Nov 2002 | WO |
2003090644 | Nov 2003 | WO |
2004030571 | Apr 2004 | WO |
2005070095 | Aug 2005 | WO |
2008042266 | Apr 2008 | WO |
2010130297 | Nov 2010 | WO |
2013045262 | Apr 2013 | WO |
2013052528 | Apr 2013 | WO |
2013066883 | Oct 2013 | WO |
2015184154 | Dec 2015 | WO |
2019099080 | May 2019 | WO |
2020146261 | Jul 2020 | WO |
2022093710 | May 2022 | WO |
Entry |
---|
European Examination Report dated Feb. 18, 2015 for EP09791142.4. |
European Examination Report dated Apr. 26, 2021 for EP11846358.7. |
European Search Report dated Mar. 19, 2021 for EP18768455.0. |
European Search Report dated Apr. 24, 2020 for EP17857414.1. |
European Search Report dated Nov. 9, 2020 for EP18767753.9. |
European Search Report dated Dec. 15, 2020 for EP18768455.0. |
European Search Reported Sep. 24, 2018 for EP16759580. |
International Preliminary Report dated May 15, 2014 for PCT/US2012/062603. |
International Publication and Search Report Jun. 14, 2012 for WO2012078794. |
International Publication and Search Report dated Feb. 25, 2012 for WO2010021836. |
International Publication and Search Report dated Aug. 4, 2005 for WO2005070095. |
International Search Report and Written Opinion dated Jan. 9, 2018 for PCT/US2017/054000. |
International Search Report and Written Opinion dated Mar. 16, 2012 for PCT/US2011/063799. |
International Search Report and Written Opinion dated Mar. 29, 2013 for PCT/US2012/062603. |
International Search Report and Written Opinion dated Jun. 22, 2016 for PCT/US2016/020900. |
International Search Report and Written Opinion dated Jun. 29, 2018 for PCT/US2018/022340. |
International Search Report and Written Opinion dated Jun. 29, 2018 for PCT/US2018/022344. |
International Search Report and Written Opinion dated Aug. 2, 2018 for PCT/US2018/028107. |
International Search Report and Written Opinion dated Sep. 28, 2005 for PCT/US2005/000515. |
International Search Report and Written Opinion dated Oct. 29, 2009 for PCT/US2009/052691. |
International Search Report and Written Opinion dated Nov. 23, 2006 for PCT/US2006/018811. |
Notice of Allowance dated Jan. 14, 2015 for U.S. Appl. No. 11/432,964. |
Notice of Allowance dated Feb. 25, 2019 for U.S. Appl. No. 15/061,107. |
Notice of Allowance dated Mar. 6, 2013 for U.S. Appl. No. 12/535,980. |
Notice of Allowance dated Jun. 11, 2013 for U.S. Appl. No. 10/585,430. |
Notice of Allowance dated Jul. 22, 2020 for U.S. Appl. No. 15/718,419. |
Notice of Allowance dated Aug. 12, 2015 for U.S. Appl. No. 13/664,200. |
Notice of Allowance dated Sep. 6, 2018 for U.S. Appl. No. 29/597,873. |
Notice of Allowance dated Mar. 15, 2023 for U.S. Appl. No. 16/994,260. |
European Examination Report dated Feb. 2, 2023 for EP18768455.0. |
International Search Report and Written Opinion dated Feb. 14, 2022 for PCT/US2021/056495. |
International Search Report and Written Opinion dated Nov. 9, 2021 for PCT/US2021/042833. |
Office Action dated Apr. 15, 2022 for U.S. Appl. No. 15/921,220. |
Office Action dated Nov. 9, 2021 for U.S. Appl. No. 15/921,221. |
Office Action dated Nov. 25, 2022 for U.S. Appl. No. 16/994,260. |
Office Action dated Sep. 14, 2023 for U.S. Appl. No. 17/509,749. |
Notice of Allowance dated Jun. 22, 2016 for U.S. Appl. No. 13/664,267. |
Notice of Allowance dated Sep. 23, 2016 for U.S. Appl. No. 13/664,234. |
Notice of Allowance dated Oct. 21, 2014 for U.S. Appl. No. 13/313,929. |
Office Action dated Jan. 3, 2014 for U.S. Appl. No. 11/432,964. |
Office Action dated Jan. 22, 2013 for U.S. Appl. No. 10/585,430. |
Office Action dated Jan. 31, 2012 for U.S. Appl. No. 10/585,430. |
Office Action dated Feb. 5, 2020 for U.S. Appl. No. 15/921,172. |
Office Action dated Mar. 6, 2020 for U.S. Appl. No. 15/955,895. |
Office Action dated Mar. 16, 2015 for U.S. Appl. No. 13/664,234. |
Office Action dated Mar. 22, 2016 for U.S. Appl. No. 13/664,234. |
Office Action dated Mar. 24, 2015 for U.S. Appl. No. 13/664,267. |
Office Action dated Apr. 6, 2016 for U.S. Appl. No. 13/664,137. |
Office Action dated Apr. 7, 2020 for U.S. Appl. No. 15/955,895. |
Office Action dated Apr. 25, 2018 for U.S. Appl. No. 15/061,107. |
Office Action dated May 5, 2014 for U.S. Appl. No. 13/313,929. |
Office Action dated May 21, 2021 for U.S. Appl. No. 15/921,220. |
Office Action dated May 25, 2012 for U.S. Appl. No. 12/535,980. |
Office Action dated May 30, 2019 for U.S. Appl. No. 15/263,741. |
Office Action dated Jun. 7, 2011 for U.S. Appl. No. 10/585,430. |
Office Action dated Jul. 9, 2009 for U.S. Appl. No. 11/432,964. |
Office Action dated Jul. 25, 2013 for U.S. Appl. No. 11/432,964. |
Office Action dated Aug. 13, 2012 for U.S. Appl. No. 10/585,430. |
Office Action dated Sep. 19, 2018 for U.S. Appl. No. 15/061,107. |
Office Action dated Oct. 7, 2015 for U.S. Appl. No. 13/664,234. |
Office Action dated Oct. 16, 2015 for U.S. Appl. No. 13/664,267. |
Office Action dated Oct. 16, 2017 for U.S. Appl. No. 15/061,107. |
Office Action dated Nov. 9, 2010 for U.S. Appl. No. 10/585,430. |
Office Action dated Nov. 14, 2012 for U.S. Appl. No. 12/535,980. |
Office Action dated Nov. 14, 2018 for U.S. Appl. No. 15/263,741. |
Office Action dated Nov. 19, 2015 for U.S. Appl. No. 13/664,137. |
Office Action dated Nov. 30, 2016 for U.S. Appl. No. 13/664,137. |
Office Action dated Dec. 2, 2019 for U.S. Appl. No. 15/718,419. |
Office Action dated Dec. 7, 2009 for U.S. Appl. No. 11/432,964. |
Office Action dated Dec. 8, 2009 for U.S. Appl. No. 10/585,430. |
Office Action dated Dec. 22, 2020 for U.S. Appl. No. 15/921,220. |
Cheon, et al., Clinical Feasibility of a New Through-The-Scope Fully Covered Esophageal Self-Expandable Metallic Stent: An In Vivo Animal Study, Digestive Endoscopy, vol. 26 No. 1 ,2014 ,32-36. |
Kawakami, et al., Endoscopic Ultrasound-Guided Transluminal Drainage for Peripancreatic Fluid Collections: Where are we now?, Gut and Liver, vol. 8 No. 4 ,2014 ,341-355. |
Sen, et al., Laplace's Equation for Convective Scalar Transport in Potential Flow, Proc. R. Soc. Lond. A 456, pp. 3041-3045 ,2000. |
Sizarov, et al., Novel materials and Devices in the Transcatheter Creation of vascular Anastomosis—The Future Comes Slowly (Part 2), Archives of Cardiovascular Diseases, vol. 109 No. 4 ,2016 ,286-295. |
Weilert, et al., Specially Designed Stents for Translumenal Drainage, Gastrointestinal Intervention, vol. 4 No. 1 ,2015,40-45. |
Notice of Allowance dated Jan. 8, 2024 for U.S. Appl. No. 17/509,749. |
European Search Report dated Jul. 5, 2024 for EP21847135.7. |
Number | Date | Country | |
---|---|---|---|
20220023026 A1 | Jan 2022 | US |
Number | Date | Country | |
---|---|---|---|
63056471 | Jul 2020 | US |